Next Article in Journal
Exploring the Antimicrobial and Anticancer Potential of a Bioactive Peptide from T. radiatus: A Comprehensive Study
Previous Article in Journal
Content Marketing in the Digital Transformation Era: Trends and Best Practices
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Noncoding Regulatory Mutations as a Driving Event for the Oncogenic Core Regulatory Circuitries of Neuroblastoma †

by
Vincenzo Aievola
1,
Vito Alessandro Lasorsa
2,
Annalaura Montella
3,
Ferdinando Bonfiglio
3,
Marianna Avitabile
3,
Teresa Maiorino
3,
Matilde Tirelli
4,
Giuseppe D’Alterio
4,
Matthias Fischer
5,
Frank Westermann
6,
Achille Iolascon
3 and
Mario Capasso
3,*
1
Department of Electrical Engineering and Information Technologies, University of Naples Federico II, Naples 80125, Italy
2
CEINGE Biotecnologie Avanzate Franco Salvatore s.c.ar.l., Naples 80131, Italy
3
Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples 80131, Italy
4
European School of Molecular Medicine, University of Milan, Milan 20139, Italy
5
Experimental Pediatric Oncology, Children’s Hospital and Center for Molecular Medicine, Medical Faculty, University of Cologne, Cologne 50937, Germany
6
Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg 69120, Germany
*
Author to whom correspondence should be addressed.
Presented at the 4th International Electronic Conference on Cancers, 6–8 March 2024; Available online: https://sciforum.net/event/IECC2024.
Proceedings 2024, 100(1), 18; https://doi.org/10.3390/proceedings2024100018
Published: 27 March 2024

1. Introduction

Neuroblastoma (NB) is a pediatric tumor composed of adrenergic (ADRN) and mesenchymal-like (MES) cells which derive from the dysregulation of normal cell differentiation imposed by NB Core Regulatory Circuitries (CRCs). We hypothesize that somatic single-nucleotide variants (SNVs) in active CRCs transcription factor binding sites (aTFBSs) may underlie such perturbation, promoting NB tumorigenesis. We aim to investigate such patterns of regulatory elements and identify putative driver SNVs, exploring their role in NB.

2. Methods

MES and ADRN aTFBSs were identified by integrating 42 ChIP-seq and 12 ATAC-seq experiments in 7 ADRN and 2 MES NB cell lines. Using the Fisher test, we tested these regions for an enrichment of somatic SNVs obtained from the WGS data of 397 NB patients. SNVs were selected based on their impact on CRC TF binding through the FABIAN-variant tool. Next, aTFBS target genes were identified by analyzing the promoter capture HiC (CHiC) in 2 ADRN and 2 MES NB cell lines and their expression values were correlated with clinical and survival data of a second cohort of 498 NBs.

3. Results

We found a significant enrichment of SNVs (FDR ≤ 0.1) in six aTFBS sets bound by 5 ADRN (GATA3, HAND2, ISL1, MYCN, and TBX2) and 1 MES (FOSL2) TFs. 689 mutations impacting the binding of CRC TFs (Fabian ≠ 0) were localized in aTFBSs interacting with genes of neuronal differentiation and MES proliferation pathways, suggesting the potential impact of SNVs on NB cell identities. By focusing on genes of developmental and differentiation processes interacting with aTFBSs carrying SNVs with the highest (cut-off ≥ 0.1) or the lowest (cut-off ≤ −0.1) Fabian score, we found targets (ROBO2, CACNB1, PIK3R1, MDGA1, HES6, LDLRAD4, DGUOK, IRX1, and SPOCK2) whose expression significantly correlated with worse NB outcomes (FDR ≤ 0.05).

4. Conclusions

These results demonstrated that somatic noncoding SNVs may act synergistically to affect NB CRCs and thus contribute to tumorigenesis.

Author Contributions

Conceptualization, M.C.; methodology, V.A.; validation, V.A.L. and F.B.; formal analysis, V.A.; investigation, A.M., M.A., T.M., G.D. and M.T.; resources, M.C., M.F. and F.W.; data curation, M.C., M.F. and F.W.; writing—original draft preparation, V.A.; writing—review and editing, M.C.; supervision, M.C.; project administration, M.C. and A.I.; funding acquisition, M.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Associazione Italiana per la Ricerca sul Cancro grant number IG 2021 ID25796 and Associazione Oncologia Pediatrica e Neuroblastoma.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Ospedale Bambino Gesù of Rome (protocol no. 20757 of the 9 April 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Public WGS data presented in the study are openly available in the the European Genome-phenome Archive (EGA) under accessions EGAD00001001687, EGAD00001006739, EGAD00001006626 and in the database of Genotypes and Phenotypes (dbGaP) under accession no.: phs000218.v21.p7; project ID: #14831. Public ChIP-seq data are available in the NCBI Gene Expression Omnibus (GEO) under accession nos.: GSE94824, GSE169616, GSE80151, GSE94782, GSE120074, GSE65664, GSE138315. Public ATAC-seq data are available in the NCBI Gene Expression Omnibus (GEO) under accessions nos.: GSE94824, GSE80152, GSE138315. Public RNA-seq data are available in the NCBI Gene Expression Omnibus (GEO) under accession no.: GSE62564. The in-house generated raw WGS, ChIP-seq, ATAC-seq and CHiC data supporting the conclusions of this article will be made available by the corresponding author on request.

Conflicts of Interest

The authors declare no conflict of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Aievola, V.; Lasorsa, V.A.; Montella, A.; Bonfiglio, F.; Avitabile, M.; Maiorino, T.; Tirelli, M.; D’Alterio, G.; Fischer, M.; Westermann, F.; et al. Noncoding Regulatory Mutations as a Driving Event for the Oncogenic Core Regulatory Circuitries of Neuroblastoma. Proceedings 2024, 100, 18. https://doi.org/10.3390/proceedings2024100018

AMA Style

Aievola V, Lasorsa VA, Montella A, Bonfiglio F, Avitabile M, Maiorino T, Tirelli M, D’Alterio G, Fischer M, Westermann F, et al. Noncoding Regulatory Mutations as a Driving Event for the Oncogenic Core Regulatory Circuitries of Neuroblastoma. Proceedings. 2024; 100(1):18. https://doi.org/10.3390/proceedings2024100018

Chicago/Turabian Style

Aievola, Vincenzo, Vito Alessandro Lasorsa, Annalaura Montella, Ferdinando Bonfiglio, Marianna Avitabile, Teresa Maiorino, Matilde Tirelli, Giuseppe D’Alterio, Matthias Fischer, Frank Westermann, and et al. 2024. "Noncoding Regulatory Mutations as a Driving Event for the Oncogenic Core Regulatory Circuitries of Neuroblastoma" Proceedings 100, no. 1: 18. https://doi.org/10.3390/proceedings2024100018

Article Metrics

Back to TopTop